The proposed new guidelines for Special Pricing Arrangements say they will be in place until a medicine moves to F2 or for a "maximum" of three years. …
Latest Video
New Stories
-
Myrio Therapeutics partners with leading US research institutions to advance T cell immunotherapies for solid tumours
October 28, 2025 - - Australian Biotech -
MTPConnect signs cooperation agreement with Saudi Ministry of Health to boost life sciences collaboration
October 28, 2025 - - Australian Biotech -
Australians want better access to medical technology, and a clearer pathway to get there
October 28, 2025 - -
Pharmacy Guild backs expanded prescribing rights for optometrists
October 28, 2025 - - Latest News -
PYC reports strong clinical momentum and cash position ahead of key readouts
October 27, 2025 - - Australian Biotech -
Government backs new national push to close bone health testing gap for women
October 27, 2025 - - Latest News -
Leadership change at PolyNovo as long-time Chair steps down
October 27, 2025 - - Australian Biotech